Compare Crispr Therapeutics AG (CRSP) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs J M Smucker Co — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while J M Smucker Co trades at $119.83 (market cap $12.76B). The key difference: J M Smucker Co is far larger — about 2.6× Crispr Therapeutics AG's market cap, and J M Smucker Co pays a 3.75% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and J M Smucker Co for 74 Days on average.
| CRSP | SJM | |
|---|---|---|
Market Cap | $4.88B | $12.76B |
Volume | 2,861,747 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $73.97 | $132.34 |
52-Week Low | $44.34 | $89.53 |
Typical Hold Time | 77 Days | 74 Days |
Enterprise Value | $3.30B | $19.61B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
SJM trades at $119.41, up 3.0% today, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with a consensus price target of $138.23, though high valuation ratios and recent net losses highlight fundamental challenges. Recent news highlights robust growth in segments like Uncrustables and raised fiscal 2027 guidance, but investor caution persists due to margin pressures and competitive headwinds in the consumer staples sector.
The outlook for SJM is cautiously optimistic, driven by earnings beats and strategic brand strength, but risks include volatile profitability, elevated debt, and sector competition. Upside potential exists if the company sustains revenue growth and improves net margins, aligning with analyst targets, though macroeconomic factors and execution risks could limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
